- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07943468
Extended Platelet-Rich Fibrin Membrane Versus Resorbable Novel Magnesium Membrane for Horizontal Ridge Augmentation With Simultaneous Implant Placement
Effectiveness Of Extended Platelet-Rich Fibrin Membrane Versus Resorbable Novel Magnesium Membrane for Horizontal Ridge Augmentation With Simultaneous Implant Placement
This study performed to evaluate and compare the effectiveness ofextended platelet-rich fibrin (ePRF) and novel magnesium membrane in horizontal ridge augmentation with simultaneous implant placement clinically and radiographically
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
The phenomenon of horizontal and vertical ridge resorption, following tooth extraction, has been extensively investigated. Different augmentation techniques have been developed to overcome this phenomenon on localization, extent, and configuration of the bone defect. These include insertion of bone grafts or barrier membranes in terms of guided bone regeneration.
The advancement Of guided bone regeneration has significantly expanded the range of implant applications to be a highly reliable treatment option even in areas of the jaw bone don't have sufficient bone support.The predictability that just attained if this process is successful, it could change the treatment of a compromised patient into a nearly normal challenge. Various have described to reconstruct deficient alveolar ridges. In the simultaneous treatment approach, guided bone regeneration is associated with superior outcomes when compared to other procedures and has become the treatment Of choice to provide optimal support for dental implants.
The primary alternative to an autograft is the use of allograft materials, which can obtained from either a compatible living donor or from cadaveric bone sources. Allograft materials can be prepared in three primary forms: fresh, frozen, or freeze-dried. Fresh and frozen allograft materials possess superior osteoinductive but are rarely used nowadays due to the higher risk Of a host immunogenic response, limited shelf life, and increased risk of disease transmission. Further processing of allograft material through freeze-drying can increase the shelf life of the material and decrease the immunogenicity, though at the cost of decreased osteoinductive potential, decreased structural strength, and osseointegration. Allografts have been successfully used for guided bone regeneration in bone augmentation procedure. This study performed to evaluate and compare the effectiveness of extended platelet-rich fibrin and novel magnesium membrane in horizontal ridge augmentation with simultaneous implant placement clinically and radiographically
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Al Mansurah, Egypt
- Mansoura university
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Horizontal bone width <6 mm an s than 3 mm at crest
- Sufficient vertical bone height for implant placement.
- Healthy and sufficient width Of keratini7Æd mucosa.
- Maxillary or mandibular edentulous space sufficient for prosthesis according to teeth to be restored. All patients are between 18 and 60 years
Exclusion Criteria:
- General contraindication for implant placement and/or surgical treatment.
- Ongoing Inflammatory and/or autoimmune disease of the oral cavity.
- Immunosuppressant, corticosteroid or bisphosphonate therapy.
- History of malignancy, radiotherapy or chemotherapy for treatment of malignancy within the past 5 years.
- Smokers.
- Insulin- dependent diabetes
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Group l
Group l: It will include 10 patients and they will be treated with delayed implant placement combined With guided bone regeneration and pericardium membrane (maxxeus). |
Group l: It will include 10 patients and they will be treated with delayed implant placement combined With guided bone regeneration by freeze dried bone allograft (maxgraft granules, botiss biomaterials GmbH, Berlin, Germany, part of Straumann Group, Basel, Switzerland) and pericardium membrane (maxxeus). |
|
Eksperimentell: Group II
Group II: It will include 10 patients and they will be treated with delayed implant placement combined With guided bone regeneration by dried freeze allograft and (e-PRF) membrane |
Group II: It will include 10 patients and they will be treated with delayed implant placement combined With guided bone regeneration by freeze dried bone allograft part of Straumann Group, Basel, Switzerland) and (e-PRF) membrane. |
|
Eksperimentell: Group III
Group III: It will include 10 patients and they will treated with delayed implant placement combined with GBR by dried freeze bone allograft DFBA and novel magnesium membrane NOVAMag |
roup III: It will include 10 patients and they will treated with delayed implant placement combined with guided bone regeneration by dried freezed bone allograft (maxgraft granules, botiss biomaterials GmbH, Berlin, Germany, part of Straumann Group, Basel, Switzerland) and novel magnesium membrane NOVAMag |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Radiographic assessment by cone beam computed tomography
Tidsramme: immediately postoperatively , at the 5-8 months postoperative and at one year postoperative
|
immediately postoperatively , at the 5-8 months postoperative and at one year postoperative
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Status of the peri-implant soft tissues (probing depth )
Tidsramme: 2 months and 6 months after loading.
|
2 months and 6 months after loading.
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- A010120230M
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
It will be available if it needed
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .